As shown in Fig. 3a, the mean concentration of serum exo-AnxA2 in non-cancer patients was 34.21 ± 2.238 ng/mL (n = 68), whereas that in patients with grade I, II, and III breast tumor was 63.49 ± 2.372 ng/mL (n = 16, P < 0.0001), 71.27 ± 2.548 ng/mL (n = 49, P < 0.0001), and 91.37 ± 2.852 ng/mL (n = 94, P < 0.0001), respectively. Here, ANXA2 is linked to cancer.